journal
MENU ▼
Read by QxMD icon Read
search

Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

journal
https://www.readbyqxmd.com/read/30102343/reply-to-al-hasan-and-justo
#1
Andre C Kalil, David N Gilbert, Dean L Winslow, Henry Masur, Michael Klompas
No abstract text is available yet for this article.
August 9, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30102340/ignoring-the-elephant-does-the-infectious-diseases-society-of-america-support-sepsis-3-or-pre-sepsis-criteria
#2
Majdi N Al-Hasan, Julie Ann Justo
No abstract text is available yet for this article.
August 9, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30099510/precision-surveillance-for-viral-respiratory-pathogens-virome-capture-sequencing-for-the-detection-and-genomic-characterization-of-severe-acute-respiratory-infection-in-uganda
#3
Matthew J Cummings, Rafal Tokarz, Barnabas Bakamutumaho, John Kayiwa, Timothy Byaruhanga, Nicholas Owor, Barbara Namagambo, Allison Wolf, Barun Mathema, Julius J Lutwama, Neil W Schluger, W Ian Lipkin, Max R O'Donnell
Background: Precision public health is a novel set of methods to target disease prevention and mitigation interventions to high-risk subpopulations. We applied a precision public health strategy to syndromic surveillance for severe acute respiratory infection (SARI) in Uganda by combining spatiotemporal analytics with genomic sequencing to detect and characterize viral respiratory pathogens with epidemic potential. Methods: Using a national surveillance network we identified patients with unexplained, influenza-negative SARI from 2010-2015...
August 7, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30099498/spatio-temporal-virus-surveillance-for-severe-acute-respiratory-infections-in-resource-limited-settings-how-deep-need-we-go
#4
Hans H Hirsch
No abstract text is available yet for this article.
August 7, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30099501/reply-to-steigbigel
#5
Noah Wald-Dickler, Paul Holtom, Brad Spellberg
No abstract text is available yet for this article.
August 6, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30099494/letter-to-the-editor
#6
Roy T Steigbigel, Neal H Steigbigel
No abstract text is available yet for this article.
August 6, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30084943/pharmacokinetics-of-efavirenz-400-mg-once-daily-coadministered-with-isoniazid-and-rifampicin-in-human-immunodeficiency-virus-infected-individuals
#7
Maddalena Cerrone, Xinzhu Wang, Megan Neary, Christine Weaver, Serge Fedele, Isaac Day-Weber, Andrew Owen, Andrew Hill, Myra McClure, Marta Boffito
Background: The World Health Organization recommends efavirenz 400 mg (EFV400) as first-line antiretroviral therapy, with a disclaimer that no data with anti-tuberculosis (TB) treatment exist. Many people living with human immunodeficiency virus (PLWH) require TB treatment with isoniazid (INH) and rifampicin (RIF), which affect cytochrome P450 and antiretroviral exposure. Methods: PLWH receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/EFV 600 mg with a viral load (VL) <50 copies/mL switched to TDF/FTC/EFV400...
August 6, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30084939/bacterial-cocktail-to-treat-clostridium-difficile-infection-primum-non-nocere
#8
Matthieu Million, Jean-Christophe Lagier, Hervé Chaudet, Didier Raoult
No abstract text is available yet for this article.
August 6, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30084937/reply-to-glim%C3%A3-ker-and-sj%C3%A3-lin
#9
Matthijs C Brouwer, Diederik van de Beek
No abstract text is available yet for this article.
August 6, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30084922/lumbar-puncture-is-safe-in-bacterial-meningitis-impaired-mental-status-alone-does-not-motivate-cranial-computed-tomography-before-lumbar-puncture
#10
Martin Glimåker, Jan Sjölin
No abstract text is available yet for this article.
August 6, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30084881/reply-to-million-et-al
#11
Erik R Dubberke, Ken Blount, Dale N Gerding
No abstract text is available yet for this article.
August 6, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30084971/the-utility-of-screening-for-coccidioidomycosis-in-recipients-of-inhibitors-of-tumor-necrosis-factor-%C3%AE
#12
Kristal Choi, Neha Deval, Anuj Vyas, Conor Moran, Stephen S Cha, Lester E Mertz, Shabana F Pasha, James A Yiannias, Janis E Blair
Background: Tumor necrosis factor-α inhibitors (TNFi) are commonly used to treat immune-mediated disorders, but they are associated with an increased risk of mycobacterial and fungal infections. We compared outcomes of TNFi recipients screened for asymptomatic coccidioidomycosis with those of unscreened patients to compare development of symptomatic coccidioidomycosis and to describe outcomes for patients with abnormal coccidioidal screening. Methods: We searched electronic health records from September 4, 2010, through September 26, 2016, for all patients receiving a TNFi for dermatologic, rheumatologic, or gastroenterologic diagnoses and then categorized patients by whether or not they had undergone coccidioidal serologic testing for screening or diagnostic purposes...
August 2, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30084883/molecular-based-testing-for-sexually-transmitted-infections-using-samples-previously-collected-for-vaginitis-diagnosis
#13
Barbara Van Der Pol, Grace Daniel, Salma Kodsi, Sonia Paradis, Charles K Cooper
Background: Vaginal symptoms are a leading cause of primary care visits for women. Individuals exhibiting symptoms often receive laboratory testing based on clinic-specific standards of care. Thus, women seen at a family practice clinic might only receive a vaginitis workup, whereas those seen at a sexually transmitted diseases clinic could be more likely to receive only sexually transmitted infection (STI) testing. Methods: The likelihood of STIs was assessed in women from whom samples were tested for vaginitis using a molecular diagnostic assay...
August 2, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30084884/a-therapeutic-strategy-for-all-pneumonia-patients-a-3-year-prospective-multicenter-cohort-study-using-risk-factors-for-multidrug-resistant-pathogens-to-select-initial-empiric-therapy
#14
Takaya Maruyama, Takao Fujisawa, Tadashi Ishida, Akihiro Ito, Yoshitaka Oyamada, Kazuyuki Fujimoto, Masamichi Yoshida, Hikaru Maeda, Naoyuki Miyashita, Hideaki Nagai, Yoshifumi Imamura, Nobuaki Shime, Shoji Suzuki, Masaru Amishima, Futoshi Higa, Hiroyasu Kobayashi, Shigeru Suga, Kiyoyuki Tsutsui, Shigeru Kohno, Veronica Brito, Michael S Niederman
Background: Empiric therapy of pneumonia is currently based on the site of acquisition (community or hospital), but could be chosen, based on risk factors for multidrug-resistant (MDR) pathogens, independent of site of acquisition. Methods: We prospectively applied a therapeutic algorithm based on MDR risks, in a multicenter cohort study of 1,089 patients, with community-acquired pneumonia (CAP, n=656), health care-associated pneumonia (HCAP, n=238), hospital-acquired pneumonia (HAP, n=140) and ventilator-associated pneumonia (VAP, n=55)...
August 1, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30084882/brain-perfusion-regional-volumes-and-cognitive-function-in-hiv-positive-patients-treated-with-protease-inhibitor-monotherapy
#15
Lewis J Haddow, Claudia Godi, Magdalena Sokolska, M Jorge Cardoso, Ruth Oliver, Alan Winston, Wolfgang Stöhr, Amanda Clarke, Fabian Chen, Ian G Williams, Margaret Johnson, Nick Paton, Alejandro Arenas-Pinto, Xavier Golay, Hans Rolf Jäger
Background: Protease inhibitor monotherapy (PIM) for HIV may exert suboptimal viral control in the central nervous system. We determined whether cerebral blood flow (CBF) and regional brain volumes were associated with PIM, and whether specific cognitive domains were associated with imaging biomarkers. Methods: Cognitive assessment and brain MRI were performed after the final visit of a randomized HIV treatment strategy trial. Participants were virologically suppressed on triple therapy at trial entry and followed for 3-5 years...
July 31, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30060092/delafloxacin-a-new-anti-mrsa-fluoroquinolone
#16
Louis D Saravolatz, Gary E Stein
Delafloxacin (ABT 492) is a new fluoroquinolone available in both oral and parenteral formulations. It has recently been approved by the FDA for the management of acute bacterial skin and skin structure infections. When compared to combination therapy of vancomycin and aztreonam, delafloxacin was not inferior and had a favorable adverse event profile. Furthermore, its anti-MRSA activity and favorable clinical response in MRSA infections distinguishes it from other fluoroquinolones. This review focuses on the mode of action, antimicrobial activity, pharmacokinetics and pharmacodynamics, clinical indications, and safety profile of this drug...
July 28, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30060032/mortality-among-patients-with-chronic-hepatitis-b-chb-infection-the-chronic-hepatitis-cohort-study-checs
#17
Danae Bixler, Yuna Zhong, Kathleen N Ly, Anne C Moorman, Philip R Spradling, Eyasu H Teshale, Loralee B Rupp L, Stuart C Gordon, Joseph A Boscarino, Mark A Schmidt, Yihe G Daida, Scott D Holmberg
Background: According to death certificates, approximately 1800 persons die from hepatitis B annually in the United States (US); however, this figure may underestimate the true mortality from chronic hepatitis B (CHB). Methods: We analyzed data from CHB patients seen in the Chronic Hepatitis Cohort Study (CHeCS) between January 1, 2006 and December 31, 2013. We compared overall and cause-specific death rates and mean age at death between CHeCS CHB decedents and US decedents from the multiple cause of death (MCOD) file...
July 28, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30060027/evolution-of-protease-inhibitor-resistance-in-hiv-1-infected-patients-failing-protease-inhibitor-monotherapy-as-second-line-therapy-in-low-income-countries-an-observational-analysis-within-the-earnest-randomised-trial
#18
Jennifer A Thompson, Cissy Kityo, David Dunn, Anne Hoppe, Emmanuel Ndashimye, James Hakim, Andrew Kambugu, Joep J van Oosterhout, Jose Arribas, Peter Mugyenyi, A Sarah Walker, Nicholas I Paton
Background: Limited viral load (VL) testing in HIV-infected individuals on treatment in low-income countries often results in late detection of treatment failure. The impact of remaining on failing second-line, protease inhibitor (PI) containing regimens is unclear. Methods: We retrospectively tested VL from 2,164 stored plasma samples from 386 patients randomised to receive PI-monotherapy (ritonavir-boosted lopinavir, after initial PI+raltegravir induction) in the EARNEST trial...
July 28, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30060087/a-randomized-clinical-trial-of-infrared-coagulation-ablation-versus-active-monitoring-of-intra-anal-high-grade-dysplasia-in-hiv-infected-adults-an-aids-malignancy-consortium-trial
#19
Stephen E Goldstone, Shelly Y Lensing, Elizabeth A Stier, Teresa Darragh, Jeannette Y Lee, Annemieke van Zante, Naomi Jay, J Michael Berry-Lawhorn, Ross D Cranston, Ronald Mitsuyasu, David Aboulafia, Joel M Palefsky, Timothy Wilkin
Background: Anal high-grade dysplasia (HSIL) ablation may reduce the incidence of invasive cancer, but few data exist on HSIL treatment efficacy and natural regression without treatment. Methods: An open-label, randomized, multi-site clinical trial of HIV-infected adults age 27 or older with 1-3 biopsy-proven anal HSIL (index HSIL) without prior history of HSIL treatment with infrared coagulation. Participants were randomized 1:1 to ablation of anal HSIL with infrared coagulation (treatment group) or no HSIL treatment (active monitoring)...
July 27, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/30060067/a-tale-of-two-healthcare-associated-infections-clostridium-difficile-coinfection-among-patients-with-candidemia
#20
Sharon Tsay, Sabrina R Williams, Kaitlin Benedict, Zintars Beldavs, Monica Farley, Lee Harrison, William Schaffner, Ghinwa Dumyati, Anna Blackstock, Alice Guh, Snigdha Vallabhaneni
Candidemia and Clostridium difficile infection (CDI) are important healthcare-associated infections that share certain risk factors. We sought to describe candidemia-CDI coinfection using population-based surveillance data. We found that nearly one in ten patients with candidemia had CDI coinfection.
July 27, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
journal
journal
20074
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"